- Home
- LFT vs CRDF Comparison
LFT vs CRDF Comparison
Compare LFT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- CRDF
- Stock Information
- Founded
- LFT 2012
- CRDF 1999
- Country
- LFT United States
- CRDF United States
- Employees
- LFT N/A
- CRDF N/A
- Industry
- LFT Real Estate Investment Trusts
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFT Real Estate
- CRDF Health Care
- Exchange
- LFT Nasdaq
- CRDF Nasdaq
- Market Cap
- LFT 122.0M
- CRDF 144.4M
- IPO Year
- LFT N/A
- CRDF N/A
- Fundamental
- Price
- LFT $2.32
- CRDF $2.05
- Analyst Decision
- LFT Hold
- CRDF Strong Buy
- Analyst Count
- LFT 2
- CRDF 5
- Target Price
- LFT N/A
- CRDF $11.10
- AVG Volume (30 Days)
- LFT 112.7K
- CRDF 1.1M
- Earning Date
- LFT 11-11-2025
- CRDF 11-06-2025
- Dividend Yield
- LFT 10.34%
- CRDF N/A
- EPS Growth
- LFT N/A
- CRDF N/A
- EPS
- LFT 0.18
- CRDF N/A
- Revenue
- LFT $25,803,999.00
- CRDF $545,000.00
- Revenue This Year
- LFT $124.75
- CRDF N/A
- Revenue Next Year
- LFT N/A
- CRDF N/A
- P/E Ratio
- LFT $12.89
- CRDF N/A
- Revenue Growth
- LFT N/A
- CRDF N/A
- 52 Week Low
- LFT $2.05
- CRDF $1.90
- 52 Week High
- LFT $2.84
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- LFT 56.45
- CRDF 36.50
- Support Level
- LFT $2.30
- CRDF $2.03
- Resistance Level
- LFT $2.37
- CRDF $2.27
- Average True Range (ATR)
- LFT 0.06
- CRDF 0.12
- MACD
- LFT 0.01
- CRDF 0.04
- Stochastic Oscillator
- LFT 82.81
- CRDF 31.91
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.